# MXD3

## Overview
MXD3, or MAX dimerization protein 3, is a gene that encodes a transcription factor involved in the MYC/MAX/MXD transcriptional network. The protein product, MAX dimerization protein 3, is characterized by a basic-helix-loop-helix leucine zipper (bHLHZ) domain, which facilitates its dimerization with the MAX cofactor, enabling it to bind DNA at E-box promoter sequences (Ngo2019Alternative; Wu2021MXD3). This interaction is crucial for its role in regulating gene expression, particularly in processes related to cell proliferation and differentiation. MXD3 is expressed in specific patterns during embryonic development and is notably active in the nervous system, where it influences the proliferation of cerebellar granule neuron precursors (Prochownik2022Normal). The gene undergoes alternative splicing, resulting in different isoforms that exhibit distinct nuclear localizations and functional roles (Ngo2019Alternative). MXD3's involvement in cancer, through genetic alterations and its role as an oncogene, underscores its clinical significance, particularly as a potential prognostic marker in various cancers (Duong2017Novel; Wu2021MXD3).

## Structure
The MXD3 gene encodes a transcription factor that is part of the MYC/MAX/MXD transcriptional network. MXD3 is characterized by a basic-helix-loop-helix leucine zipper (bHLHZ) domain, which facilitates dimerization with the MAX cofactor and enables DNA binding at E-box promoter sequences (Ngo2019Alternative; Wu2021MXD3). This structure is crucial for its function in regulating gene expression.

MXD3 undergoes alternative splicing, resulting in two splice variants: MXD3.E6 and MXD3.E7. MXD3.E6 includes exons 1-6 and encodes a 206 amino acid protein, while MXD3.E7 includes exons 1-5 and exon 7, resulting in a 193 amino acid protein with a different C-terminus (Ngo2019Alternative). These isoforms exhibit differential post-translational modifications, particularly phosphorylation. MXD3.E7 is phosphorylated, as indicated by a band shift upon phosphatase treatment, whereas MXD3.E6 is not (Ngo2019Alternative).

The two isoforms also differ in their nuclear localization. MXD3.E7 is distributed throughout the nucleus, while MXD3.E6 forms nuclear foci, some of which are associated with promyelocytic leukemia protein (PML) bodies (Ngo2019Alternative). These structural differences suggest distinct functional roles for the MXD3 isoforms in cellular processes.

## Function
MXD3 (MAX dimerization protein 3) is a transcription factor involved in regulating cell proliferation and differentiation. It functions by forming heterodimers with MAX, influencing gene expression through interactions with chromatin-modifying complexes. In healthy cells, MXD3 is expressed in specific patterns during embryonic development, particularly in quiescent compartments, contrasting with the proliferative compartments where Myc and Mycn are expressed (Prochownik2022Normal). This expression pattern suggests a role in maintaining cellular quiescence and regulating the balance between proliferation and differentiation.

MXD3 is active in the nucleus and plays a crucial role in the nervous system, where it is required for the proliferation of cerebellar granule neuron precursors (GNPs). It can drive proliferation even in the absence of Sonic Hedgehog (Shh) signaling, indicating that MXD3 may complement Mycn's role in promoting cell proliferation (Prochownik2022Normal). The expression of MXD3 is regulated by an E2F1 binding site in its promoter, linking it to cell cycle regulation (Prochownik2022Normal).

Despite its roles in proliferation and differentiation, the full function of MXD3 in healthy human cells remains not fully understood, and its potential pro-oncogenic roles in cancer highlight the complexity of its function (Prochownik2022Normal).

## Clinical Significance
MXD3 (MAX dimerization protein 3) is implicated in various cancers due to its role as an oncogene. Alterations in MXD3, such as gene amplification, mutations, and deletions, are common in cancer, with gene amplification being the most prevalent. These alterations contribute to tumor progression, invasion, and metastasis across multiple cancer types (Wu2021MXD3). High MXD3 expression is associated with poor prognosis in cancers like gliomas, neuroblastoma, and diffuse large B-cell lymphoma, indicating its potential as a prognostic marker (Zhang2021MXD3; Duong2017Novel).

In neuroblastoma, high MXD3 expression correlates with high-risk disease and poor outcomes. Targeting MXD3 with siRNA nanocomplexes has shown promise in inducing apoptosis and enhancing chemotherapy efficacy (Duong2017Novel). In gliomas, MXD3 expression increases with malignancy and is linked to worse outcomes, particularly in cases with IDH mutations and 1p19q codeletion (Zhang2021MXD3).

MXD3 also plays a role in immune evasion, with its expression affecting immune cell infiltration and response to immune checkpoint blockade therapies. High MXD3 expression is linked to worse outcomes in certain cancers treated with these therapies, although it may benefit bladder cancer patients (Wu2021MXD3).

## Interactions
MXD3 (MAX dimerization protein 3) is involved in various interactions that play a significant role in its function as a transcriptional repressor. MXD3 frequently forms heterodimers with the MAX protein, a member of the bHLHZip family of transcription factors. These heterodimers bind to E-box sequences in DNA, regulating gene expression by repressing transcription (Wu2021MXD3). The interaction between MXD3 and MAX is part of a larger network involving other proteins such as MYC and MAD, which also form dimers with MAX to influence gene transcription (Nair2024Structural).

MXD3's role in cancer is highlighted by its genetic alterations, including amplifications, mutations, and deletions, which affect its interactions and are associated with survival outcomes in cancer cohorts (Wu2021MXD3). The gene is coexpressed with several other genes, such as DBN1, RAB24, and SLC34A1, suggesting functional partnerships in its oncogenic role. These interactions are crucial for MXD3's involvement in biological processes like inorganic anion homeostasis and phospholipid transport, as well as pathways such as Rap1 signaling and chemokine signaling (Wu2021MXD3).


## References


1. (Nair2024Structural) Structural Aspects of Interactions Within the Myc/Max/Mad Network. This article has 12 citations.

[2. (Wu2021MXD3) Szu-Yuan Wu, Kuan-Chou Lin, Bashir Lawal, Alexander T.H Wu, and Ching-Zong Wu. Mxd3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types. Computational and Structural Biotechnology Journal, 19:4970–4983, 2021. URL: http://dx.doi.org/10.1016/j.csbj.2021.08.047, doi:10.1016/j.csbj.2021.08.047. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.csbj.2021.08.047)

[3. (Prochownik2022Normal) Edward V. Prochownik and Huabo Wang. Normal and neoplastic growth suppression by the extended myc network. Cells, 11(4):747, February 2022. URL: http://dx.doi.org/10.3390/cells11040747, doi:10.3390/cells11040747. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11040747)

[4. (Ngo2019Alternative) Tin Ngo, Abraham Corrales, Traci Bourne, Samir Elmojahid, Kit S. Lam, and Elva Díaz. Alternative splicing of mxd3 and its regulation of mxd3 levels in glioblastoma. Frontiers in Molecular Biosciences, February 2019. URL: http://dx.doi.org/10.3389/fmolb.2019.00005, doi:10.3389/fmolb.2019.00005. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2019.00005)

[5. (Zhang2021MXD3) Xiaoyu Zhang, Xiaoqin He, Yue Li, Yangtao Xu, Wenliang Chen, Xin Liu, Xinyao Hu, Lin Xiong, and Ximing Xu. Mxd3 as an immunological and prognostic factor from pancancer analysis. Frontiers in Molecular Biosciences, November 2021. URL: http://dx.doi.org/10.3389/fmolb.2021.702206, doi:10.3389/fmolb.2021.702206. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.702206)

[6. (Duong2017Novel) Connie Duong, Sakiko Yoshida, Cathy Chen, Gustavo Barisone, Elva Diaz, Yueju Li, Laurel Beckett, Jong Chung, Reuben Antony, Jan Nolta, Nitin Nitin, and Noriko Satake. Novel targeted therapy for neuroblastoma: silencing the mxd3 gene using sirna. Pediatric Research, 82(3):527–535, May 2017. URL: http://dx.doi.org/10.1038/pr.2017.74, doi:10.1038/pr.2017.74. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/pr.2017.74)